journal article·2024-08Open access

Fluorescence‐Guided Spatial Drug Screening in 3D Colorectal Cancer Spheroids

Jia Ning Nicolette Yau, Thirumal Yempala, Ram Pravin Kumar Muthuramalingam, Giulio Giustarini, Germaine Teng, Wee Han Ang, Dan Gibson, Giulia Adriani, Giorgia Pastorin

Advanced Healthcare Materials· Volume 13· Issue 20

Abstract

Abstract The limited recapitulation of critical cancer features in 2D cultures causes poor translatability of preclinical results from in vitro assays to in vivo tumor models. This contributes to slow drug development with a low success rate. 3D cultures better recapitulate the tumor microenvironment, enabling more accurate predictions when screening drug candidates and improving the development of chemotherapeutics. Platinum (Pt) (IV) compounds are promising prodrugs designed to reduce the severe systemic toxicity of widely used Food and Drug Administration (FDA)‐approved Pt(II) drugs such as cisplatin. Here, this work presents spatiotemporal evaluations in 3D colorectal cancer (CRC) spheroids of mitochondria‐targeting Pt(IV) complexes. CRC spheroids provide a greater pathophysiological recapitulation of in vivo tumors than 2D cultures by a marked upregulation of the ABCG2 chemoresistance marker expression. Furthermore, new 3D‐staining protocols are introduced to evaluate the real‐time decrease in mitochondria membrane potential (ΔΨ) in CRC spheroids, and a Pt‐sensing dye to quantify the Pt mitochondrial accumulation. Finally, this work demonstrates a correlation between in vitro results and the efficacy of the compounds in vivo. Overall, the CRC spheroids represent a fast and cost‐effective model to assess the behavior of Pt compounds in vitro and predict their translational potential in CRC treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy and Pharmaceutical Sciences Faculty of Science National University of Singapore Singapore 117544 Singapore

Integrative Sciences and Engineering Programme NUS Graduate School National University of Singapore Singapore 119077 Singapore

Singapore Immunology Network Agency for Science, Technology, and Research Singapore 138648 Singapore

Department of Chemistry Faculty of Science National University of Singapore Singapore 117544 Singapore

Institute for Drug Research School of Pharmacy Hebrew University of Jerusalem Jerusalem 91120 Israel

Department of Biomedical Engineering Faculty of Engineerin National University of Singapore Singapore 117578 Singapore

References (100+)

Show source-provided references
1. 10.1245/s10434-022-12151-610.1245/s10434-022-12151-6 ↗
2. 10.1136/gutjnl-2022-32773610.1136/gutjnl-2022-327736 ↗
3. 10.1038/nbt.278610.1038/nbt.2786 ↗
4. Neidle S. · 2011 · 427
5. 10.1038/nrc189310.1038/nrc1893 ↗
6. 10.1186/s13578-022-00887-310.1186/s13578-022-00887-3 ↗
7. 10.1186/s12935-021-01898-910.1186/s12935-021-01898-9 ↗
8. Kapałczyńska M. · Arch. Med. Sci. · 2018 · 14 · 910
9. 10.1158/0008-5472.CAN-13-2921-T10.1158/0008-5472.CAN-13-2921-T ↗
10. Van Weerden W. · Am. J. Pathol. · 1996 · 149 · 1055
11. 10.1002/ijc.3266210.1002/ijc.32662 ↗
12. 10.3390/cancers1501013910.3390/cancers15010139 ↗
13. 10.1080/15384047.2020.173890710.1080/15384047.2020.1738907 ↗
14. 10.1016/j.canlet.2015.06.02410.1016/j.canlet.2015.06.024 ↗
15. 10.1016/j.bej.2022.10841410.1016/j.bej.2022.108414 ↗
16. 10.1016/j.drudis.2016.05.00610.1016/j.drudis.2016.05.006 ↗
17. 10.1371/journal.pone.015004410.1371/journal.pone.0150044 ↗
18. 10.1371/journal.pone.015108910.1371/journal.pone.0151089 ↗
19. 10.1111/cas.1353310.1111/cas.13533 ↗
20. 10.1016/j.biomaterials.2010.07.05010.1016/j.biomaterials.2010.07.050 ↗
21. 10.1038/s41598-019-42836-010.1038/s41598-019-42836-0 ↗
22. 10.1038/s41598-018-35216-710.1038/s41598-018-35216-7 ↗
23. 10.3389/fonc.2017.0029310.3389/fonc.2017.00293 ↗
24. 10.1016/j.addr.2021.06.00110.1016/j.addr.2021.06.001 ↗
25. 10.1016/j.jconrel.2020.06.01110.1016/j.jconrel.2020.06.011 ↗
26. 10.3389/fphy.2015.0001510.3389/fphy.2015.00015 ↗
27. 10.1007/s00262-016-1927-110.1007/s00262-016-1927-1 ↗
28. 10.1063/5.005777310.1063/5.0057773 ↗
29. 10.3389/fimmu.2018.0041610.3389/fimmu.2018.00416 ↗
30. 10.1016/j.addr.2014.03.00110.1016/j.addr.2014.03.001 ↗
31. 10.1186/s12951-022-01692-310.1186/s12951-022-01692-3 ↗
32. 10.1016/j.nantod.2022.10145910.1016/j.nantod.2022.101459 ↗
33. 10.15252/embj.201810092810.15252/embj.2018100928 ↗
34. 10.1016/j.actbio.2020.12.03710.1016/j.actbio.2020.12.037 ↗
35. 10.1038/s41598-018-33055-010.1038/s41598-018-33055-0 ↗
36. 10.1002/adma.20190204210.1002/adma.201902042 ↗
37. 10.1371/journal.pone.015901310.1371/journal.pone.0159013 ↗
38. 10.1111/bph.1419510.1111/bph.14195 ↗
39. 10.1007/978-0-387-89445-4_610.1007/978-0-387-89445-4_6 ↗
40. 10.1016/j.mattod.2015.05.00210.1016/j.mattod.2015.05.002 ↗
41. 10.1038/s41467-022-30384-710.1038/s41467-022-30384-7 ↗
42. 10.1098/rsif.2017.013710.1098/rsif.2017.0137 ↗
43. 10.1038/s41467-023-36160-510.1038/s41467-023-36160-5 ↗
44. 10.1038/s41598-017-01256-810.1038/s41598-017-01256-8 ↗
45. 10.18632/oncotarget.2630610.18632/oncotarget.26306 ↗
46. 10.3390/bios1111044510.3390/bios11110445 ↗
47. 10.1038/srep2106110.1038/srep21061 ↗
48. 10.1038/s41416-019-0495-510.1038/s41416-019-0495-5 ↗
49. 10.1016/j.shpsc.2005.07.00310.1016/j.shpsc.2005.07.003 ↗
50. 10.1158/0008-5472.CAN-07-301810.1158/0008-5472.CAN-07-3018 ↗
51. 10.1002/smll.20200230310.1002/smll.202002303 ↗
52. 10.1038/s41467-017-00475-x10.1038/s41467-017-00475-x ↗
53. 10.1126/sciadv.aaw785310.1126/sciadv.aaw7853 ↗
54. 10.1016/j.celrep.2020.10767010.1016/j.celrep.2020.107670 ↗
55. 10.1002/anie.20190311210.1002/anie.201903112 ↗
56. 10.2165/00003495-200059004-0000210.2165/00003495-200059004-00002 ↗
57. 10.1152/ajpgi.00212.201410.1152/ajpgi.00212.2014 ↗
58. 10.1016/S0010-8545(02)00026-710.1016/S0010-8545(02)00026-7 ↗
59. 10.1016/S0162-0134(01)00360-910.1016/S0162-0134(01)00360-9 ↗
60. 10.1007/s00775-014-1214-610.1007/s00775-014-1214-6 ↗
61. 10.1002/smll.20210180410.1002/smll.202101804 ↗
62. 10.1093/carcin/13.11.196710.1093/carcin/13.11.1967 ↗
63. 10.1073/pnas.71.7.277710.1073/pnas.71.7.2777 ↗
64. 10.3390/ijms1907205010.3390/ijms19072050 ↗
65. 10.1016/j.jinorgbio.2021.11165310.1016/j.jinorgbio.2021.111653 ↗
66. 10.1016/j.msec.2016.03.07410.1016/j.msec.2016.03.074 ↗
67. 10.1002/biot.20170041710.1002/biot.201700417 ↗
68. 10.1080/17460441.2019.157012910.1080/17460441.2019.1570129 ↗
69. 10.1016/j.actbio.2021.03.03710.1016/j.actbio.2021.03.037 ↗
70. 10.3390/cancers1323595510.3390/cancers13235955 ↗
71. 10.1016/j.matbio.2018.03.01610.1016/j.matbio.2018.03.016 ↗
72. 10.1039/C5LC01569C10.1039/C5LC01569C ↗
73. aimbiotech General Protocol aimbiotech https://aimbiotech.com/wp‐content/uploads/2022/01/General‐Protocol_v6.1.pdf(accessed January 2023).
74. 10.1016/j.vascn.2016.11.00110.1016/j.vascn.2016.11.001 ↗
75. 10.3390/ijms1809192610.3390/ijms18091926 ↗
76. 10.1016/j.yexcr.2015.09.01110.1016/j.yexcr.2015.09.011 ↗
77. 10.3233/CBM-13034410.3233/CBM-130344 ↗
78. 10.1002/path.120310.1002/path.1203 ↗
79. 10.1007/BF0029624510.1007/BF00296245 ↗
80. 10.1007/s11095-010-0303-710.1007/s11095-010-0303-7 ↗
81. 10.1021/jm070827510.1021/jm0708275 ↗
82. 10.18632/oncotarget.1385710.18632/oncotarget.13857 ↗
83. 10.3390/mi903009410.3390/mi9030094 ↗
84. Erlichman C. · Cancer Res. · 1984 · 44 · 5369
85. 10.1002/cyto.99012010710.1002/cyto.990120107 ↗
86. Dzulkifli F. A. · J. Biomed. Clin. Sci. · 2019 · 3 · 10
87. Guzińska‐Ustymowicz K. · Anticancer Res. · 2009 · 29 · 3049
88. 10.3892/ol.2022.1354010.3892/ol.2022.13540 ↗
89. 10.1007/978-3-662-44559-4_2510.1007/978-3-662-44559-4_25 ↗
90. 10.4103/MJBL.MJBL_18_1810.4103/MJBL.MJBL_18_18 ↗
91. 10.1042/BST2011077310.1042/BST20110773 ↗
92. 10.1038/cdd.2008.7810.1038/cdd.2008.78 ↗
93. 10.1023/A:102294510776210.1023/A:1022945107762 ↗
94. 10.3390/ijms2014338410.3390/ijms20143384 ↗
95. 10.1002/anie.20201095110.1002/anie.202010951 ↗
96. 10.1039/C4CC08077G10.1039/C4CC08077G ↗
97. 10.1093/jat/32.2.14010.1093/jat/32.2.140 ↗
98. 10.1007/BF0062355110.1007/BF00623551 ↗
99. 10.1021/acs.analchem.7b0268110.1021/acs.analchem.7b02681 ↗
100. 10.1039/c2mt20168b10.1039/c2mt20168b ↗